UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| Date of report (Date of earliest event reported) | September 22, 2003 | |
ATRIX LABORATORIES, INC.
| Delaware | 0-18231 | 84-1043826 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File No.) | (IRS Employer Identification No.) |
| 2579 Midpoint Drive, Fort Collins, Colorado | 80525 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| Registrant’s telephone number, including area code | (970) 482-5868 | |
| Item 5. Other Events. | ||||||||
| Item 7. Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1 Press Release | ||||||||
Item 5. Other Events.
On September 22, 2003, Atrix Laboratories, Inc. (the “Company”) issued a press release announcing that it will be presenting at the UBS Warburg Global Life Sciences Conference in New York where it will be discussing the Company’s prospects, opportunities, and challenges, including the financial challenges related to the goal of breaking even for 2003 and providing an update on Eligard® (leuprolide acetate for injectable suspension) prostate cancer products. A copy of the press release is attached as Exhibit 99.1 to this report.
Item 7. Exhibits.
99.1 Press Release dated September 22, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ATRIX LABORATORIES, INC | ||||
| By: | /s/ Mark A. Wallace | |||
| Mark A. Wallace | ||||
| Chief Financial Officer | ||||
Date: September 23, 2003
EXHIBIT INDEX
| Exhibit | Description | |||||
| 99.1 | Press Release dated September 22, 2003. |